Y-mAbs Therapeutics (YMAB) Stock Forecast, Price Target & Predictions
YMAB Stock Forecast
Y-mAbs Therapeutics stock forecast is as follows: an average price target of $22.50 (represents a 171.74% upside from YMAB’s last price of $8.28) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
YMAB Price Target
The average price target for Y-mAbs Therapeutics (YMAB) is $22.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $21.00. This represents a potential 171.74% upside from YMAB's last price of $8.28.
YMAB Analyst Ratings
According to 6 Wall Street analysts, Y-mAbs Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for YMAB stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Y-mAbs Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | Etzer Darout | BMO Capital | $24.00 | $15.06 | 59.36% | 189.86% |
| Jun 28, 2024 | Nicole Germino | Truist Financial | $21.00 | $12.33 | 70.32% | 153.62% |
| May 10, 2024 | Robert Burns | H.C. Wainwright | $22.00 | $12.87 | 70.94% | 165.70% |
| Apr 05, 2024 | Etzer Darout | BMO Capital | $26.00 | $14.56 | 78.57% | 214.01% |
| May 10, 2023 | YMAB)to Outperform | Wedbush | $13.00 | $9.89 | 31.38% | 57.00% |
The latest Y-mAbs Therapeutics stock forecast, released on Nov 11, 2024 by Etzer Darout from BMO Capital, set a price target of $24.00, which represents a 59.36% increase from the stock price at the time of the forecast ($15.06), and a 189.86% increase from YMAB last price ($8.28).
Y-mAbs Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $24.00 | $23.25 |
| Last Closing Price | $8.28 | $8.28 | $8.28 |
| Upside/Downside | -100.00% | 189.86% | 180.80% |
In the current month, the average price target of Y-mAbs Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Y-mAbs Therapeutics's last price of $8.28. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 09, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
| Sep 09, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Aug 16, 2024 | Cantor Fitzgerald | Overweight | Initialise | |
| Aug 13, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Aug 13, 2024 | BMO Capital | Underperform | Underperform | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 05, 2024 | BMO Capital | Outperform | Outperform | Hold |
| May 10, 2023 | Wedbush | Outperform | Upgrade | |
| Jan 05, 2023 | Cowen & Co. | Market Perform | Downgrade | |
| Oct 31, 2022 | Guggenheim | Buy | Buy | Hold |
| Oct 31, 2022 | Guggenheim | Buy | Initialise | |
| Oct 31, 2022 | BTIG | Buy | Initialise |
Y-mAbs Therapeutics's last stock rating was published by Cantor Fitzgerald on Sep 09, 2024. The company gave YMAB a "Underperform" rating, the same as its previous rate.
Y-mAbs Therapeutics Financial Forecast
Y-mAbs Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $23.36M | $20.45M | $20.75M | $20.25M | $31.45M | $12.54M | $10.80M | $10.49M | $9.60M | $8.96M | $10.95M | $5.38M | $20.75M |
| Avg Forecast | $27.66M | $25.54M | $25.63M | $24.37M | $26.95M | $23.28M | $23.02M | $22.21M | $20.95M | $20.97M | $20.33M | $15.58M | $20.35M | $12.01M | $11.23M | $10.90M | $10.77M | $10.87M | $7.33M | $41.84M | $11.59M |
| High Forecast | $31.89M | $29.45M | $29.55M | $28.52M | $28.09M | $23.58M | $26.54M | $22.21M | $22.15M | $20.97M | $23.44M | $17.96M | $23.46M | $12.01M | $11.23M | $10.90M | $10.77M | $10.87M | $7.33M | $41.84M | $11.59M |
| Low Forecast | $25.21M | $23.28M | $23.36M | $22.20M | $24.92M | $22.97M | $20.99M | $22.21M | $19.60M | $20.97M | $18.53M | $14.20M | $18.55M | $12.01M | $11.23M | $10.90M | $10.77M | $10.87M | $7.33M | $41.84M | $11.59M |
| # Analysts | 3 | 3 | 3 | 5 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | 1.12% | 0.98% | 1.02% | 1.30% | 1.55% | 1.04% | 0.96% | 0.96% | 0.89% | 0.82% | 1.49% | 0.13% | 1.79% |
Y-mAbs Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $22.21M, with a low forecast of $22.21M, and a high forecast of $22.21M. YMAB's average Quarter revenue forecast represents a -4.95% decrease compared to the company's last Quarter revenue of $23.36M (Dec 23).
Y-mAbs Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $-74.00K | $-7.75M | $-7.22M | $-7.50M | $-1.15M | $-25.79M | $-39.76M | $-27.50M | $-35.47M | $-28.56M | $-22.50M | $33.88M | $-19.82M |
| Avg Forecast | $-12.74M | $-11.76M | $-11.80M | $-11.22M | $-12.41M | $-10.72M | $-10.60M | $-37.05M | $-9.65M | $-9.66M | $-9.36M | $-33.68M | $-30.65M | $-5.39M | $-5.03M | $-30.62M | $-4.83M | $-4.87M | $-3.28M | $-18.76M | $-5.20M |
| High Forecast | $-11.61M | $-10.72M | $-10.76M | $-10.23M | $-11.48M | $-10.58M | $-9.66M | $-29.64M | $-9.03M | $-9.66M | $-8.54M | $-26.95M | $-24.52M | $-5.39M | $-5.03M | $-24.50M | $-4.83M | $-4.87M | $-3.28M | $-18.76M | $-5.20M |
| Low Forecast | $-14.68M | $-13.56M | $-13.61M | $-13.14M | $-12.94M | $-10.86M | $-12.22M | $-44.46M | $-10.20M | $-9.66M | $-10.79M | $-40.42M | $-36.78M | $-5.39M | $-5.03M | $-36.75M | $-4.83M | $-4.87M | $-3.28M | $-18.76M | $-5.20M |
| Surprise % | - | - | - | - | - | - | - | - | 0.01% | 0.80% | 0.77% | 0.22% | 0.04% | 4.79% | 7.90% | 0.90% | 7.34% | 5.86% | 6.85% | -1.81% | 3.81% |
2 analysts predict YMAB's average Quarter EBITDA for Jun 21 to be $-3.28M, with a high of $-3.28M and a low of $-3.28M. This is -109.69% lower than Y-mAbs Therapeutics's previous annual EBITDA (Mar 21) of $33.88M.
Y-mAbs Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $-2.28M | $-7.75M | $-6.30M | $-5.10M | $-401.00K | $-29.04M | $-42.32M | $-28.44M | $-38.03M | $-28.86M | $-22.94M | $33.41M | $-19.93M |
| Avg Forecast | $-7.21M | $-7.60M | $-7.64M | $-6.90M | $-4.69M | $-7.04M | $-5.55M | $-37.31M | $-8.75M | $-8.38M | $-10.80M | $-33.92M | $-31.89M | $-31.26M | $-29.30M | $-30.84M | $-30.48M | $-25.71M | $-29.20M | $58.56M | $-20.59M |
| High Forecast | $-6.38M | $-6.72M | $-6.76M | $-1.73M | $-1.44M | $-6.23M | $-4.91M | $-29.85M | $-7.37M | $-7.42M | $-9.56M | $-27.14M | $-25.51M | $-31.26M | $-29.30M | $-24.67M | $-30.48M | $-25.71M | $-29.20M | $70.27M | $-20.59M |
| Low Forecast | $-8.64M | $-9.11M | $-9.16M | $-9.49M | $-9.01M | $-8.44M | $-6.65M | $-44.77M | $-9.21M | $-10.05M | $-12.95M | $-40.70M | $-38.26M | $-31.26M | $-29.30M | $-37.00M | $-30.48M | $-25.71M | $-29.20M | $46.85M | $-20.59M |
| Surprise % | - | - | - | - | - | - | - | - | 0.26% | 0.92% | 0.58% | 0.15% | 0.01% | 0.93% | 1.44% | 0.92% | 1.25% | 1.12% | 0.79% | 0.57% | 0.97% |
Y-mAbs Therapeutics's average Quarter net income forecast for Jun 21 is $-29.20M, with a range of $-29.20M to $-29.20M. YMAB's average Quarter net income forecast represents a -187.40% decrease compared to the company's last Quarter net income of $33.41M (Mar 21).
Y-mAbs Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $11.13M | $10.20M | $11.27M | $12.25M | $10.79M | $13.63M | $23.08M | $13.44M | $15.14M | $13.99M | $13.47M | $11.97M | $14.63M |
| Avg Forecast | $34.21M | $31.59M | $31.70M | $30.15M | $33.34M | $28.79M | $28.47M | $17.86M | $25.91M | $25.94M | $25.15M | $19.27M | $13.08M | $14.83M | $13.86M | $13.45M | $13.30M | $13.42M | $9.04M | $20.98M | $14.31M |
| High Forecast | $39.44M | $36.42M | $36.55M | $35.28M | $34.74M | $29.17M | $32.83M | $21.44M | $27.40M | $25.94M | $28.99M | $22.22M | $15.70M | $14.83M | $13.86M | $13.45M | $13.30M | $13.42M | $9.04M | $25.17M | $14.31M |
| Low Forecast | $31.19M | $28.80M | $28.90M | $27.47M | $30.82M | $28.41M | $25.96M | $14.29M | $24.24M | $25.94M | $22.92M | $17.57M | $10.47M | $14.83M | $13.86M | $13.45M | $13.30M | $13.42M | $9.04M | $16.78M | $14.31M |
| Surprise % | - | - | - | - | - | - | - | - | 0.43% | 0.39% | 0.45% | 0.64% | 0.82% | 0.92% | 1.67% | 1.00% | 1.14% | 1.04% | 1.49% | 0.57% | 1.02% |
Y-mAbs Therapeutics's average Quarter SG&A projection for Mar 24 is $17.86M, based on 2 Wall Street analysts, with a range of $14.29M to $21.44M. The forecast indicates a 60.42% rise compared to YMAB last annual SG&A of $11.13M (Dec 23).
Y-mAbs Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.14 | $-0.12 | $-0.01 | $-0.66 | $-0.97 | $-0.65 | $-0.87 | $-0.66 | $-0.53 | $0.80 | $-0.48 |
| Avg Forecast | $-0.16 | $-0.17 | $-0.17 | $-0.15 | $-0.11 | $-0.16 | $-0.12 | $-0.14 | $-0.20 | $-0.19 | $-0.24 | $-0.32 | $-0.46 | $-0.71 | $-0.67 | $-0.72 | $-0.69 | $-0.58 | $-0.66 | $0.39 | $-0.47 |
| High Forecast | $-0.14 | $-0.15 | $-0.15 | $-0.04 | $-0.03 | $-0.14 | $-0.11 | $-0.12 | $-0.17 | $-0.17 | $-0.21 | $-0.28 | $-0.40 | $-0.71 | $-0.67 | $-0.72 | $-0.69 | $-0.58 | $-0.66 | $0.39 | $-0.47 |
| Low Forecast | $-0.19 | $-0.20 | $-0.21 | $-0.21 | $-0.20 | $-0.19 | $-0.15 | $-0.16 | $-0.21 | $-0.23 | $-0.29 | $-0.38 | $-0.55 | $-0.71 | $-0.67 | $-0.72 | $-0.69 | $-0.58 | $-0.66 | $0.39 | $-0.47 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.58% | 0.38% | 0.02% | 0.93% | 1.46% | 0.91% | 1.26% | 1.13% | 0.80% | 2.07% | 1.02% |
According to 2 Wall Street analysts, Y-mAbs Therapeutics's projected average Quarter EPS for Jun 21 is $-0.66, with a low estimate of $-0.66 and a high estimate of $-0.66. This represents a -182.92% decrease compared to YMAB previous annual EPS of $0.80 (Mar 21).
Y-mAbs Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
| STRO | Sutro Biopharma | $2.09 | $13.00 | 522.01% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| YMAB | Y-mAbs Therapeutics | $9.53 | $22.50 | 136.10% | Buy |
| SNDX | Syndax Pharmaceuticals | $13.63 | $31.67 | 132.36% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $3.13 | $7.00 | 123.64% | Buy |
| ARQT | Arcutis Biotherapeutics | $14.86 | $31.00 | 108.61% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| MRUS | Merus | $44.90 | $81.25 | 80.96% | Buy |
| PCVX | Vaxcyte | $89.86 | $148.80 | 65.59% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| BLUE | bluebird bio | $8.97 | $13.69 | 52.62% | Hold |
| MRSN | Mersana Therapeutics | $2.03 | $3.00 | 47.78% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
| MIRM | Mirum Pharmaceuticals | $42.65 | $57.00 | 33.65% | Buy |
| TVTX | Travere Therapeutics | $17.14 | $21.75 | 26.90% | Buy |
| KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |